Arrowhead Pharmaceuticals, Inc. (ARWR): Price and Financial Metrics

Arrowhead Pharmaceuticals, Inc. (ARWR)

Today's Latest Price: $45.75 USD

1.68 (-3.54%)

Updated Sep 17 6:55pm

Add ARWR to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 373 in Biotech

See all "A" rated Strong Buy stocks

ARWR Stock Summary

  • ARWR's price/sales ratio is 37.85; that's higher than the P/S ratio of 95.1% of US stocks.
  • ARWR's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of merely 11.07% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Arrowhead Pharmaceuticals Inc is reporting a growth rate of -182.7%; that's higher than merely 10.24% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Arrowhead Pharmaceuticals Inc, a group of peers worth examining would be ARVN, CUE, ZYME, ACRS, and BLUE.
  • ARWR's SEC filings can be seen here. And to visit Arrowhead Pharmaceuticals Inc's official web site, go to
ARWR Daily Price Range
ARWR 52-Week Price Range

ARWR Stock Price Chart Technical Analysis Charts

ARWR Price/Volume Stats

Current price $45.75 52-week high $73.72
Prev. close $47.43 52-week low $19.51
Day low $45.55 Volume 2,649,900
Day high $48.95 Avg. volume 1,486,986
50-day MA $42.95 Dividend yield N/A
200-day MA $42.09 Market Cap 4.68B

Arrowhead Pharmaceuticals, Inc. (ARWR) Company Bio

Arrowhead Pharmaceuticals is a biopharmaceutical company developing targeted RNAi therapeutics. The company was founded in 1989 and is based in Pasadena, California.

ARWR Latest News Stream

Event/Time News Detail
Loading, please wait...

ARWR Latest Social Stream

Loading social stream, please wait...

View Full ARWR Social Stream

Latest ARWR News From Around the Web

Below are the latest news stories about Arrowhead Pharmaceuticals Inc that investors may wish to consider to help them evaluate ARWR as an investment opportunity.

INO, ARWR, ADT and AXL among midday movers

Gainers: Arrowhead Pharmaceuticals (ARWR) +47%.Eastman Kodak (KODK) +39%.Myomo (MYO) +35%.Inovio Pharmaceuticals (INO) +27%.Renren (RENN) +25%.AMC Networks (AMCX) +22%.Pacific Ethanol (PEIX) +22%.Histogen (HSTO) +21%.Heat Biologics (HTBX) +16%.Ossen Innovation (OSN) +16%.Losers: Novus Therapeutics (NVUS) -17%.ADT (ADT) -13%.American Axle & Manufacturing (AXL) -12%.Forterra (FRTA) -10%.8i Enterprises Acquisition (JFK) -10%.Francesca's (FRAN) -10%.Grupo Supervielle (SUPV) -9%.89bio (ETNB) -9%.Jounce Therapeutics (JNCE) -9%.Empresa Distribuidora (EDN) -6%....

Seeking Alpha | September 16, 2020

Arrowhead Pharmaceuticals, Myomo leads healthcare gainers, Novus Therapeutics, Jounce Therapeutics among major losers

Gainers: Arrowhead Pharmaceuticals (ARWR) +46%, Myomo (MYO) +38%, AxoGen (AXGN) +15%, Covetrus (CVET) +14%, Inovio Pharmaceuticals (INO) +13%.Losers: Novus Therapeutics (NVUS) -13%, Jounce Therapeutics (JNCE) -10%, Syneos Health (SYNH) -7%, Verastem (VSTM) -5%, Evogene (EVGN) -5%....

Seeking Alpha | September 16, 2020

Arrowhead Pharma Reveals Positive Data On Drug To Treat Liver Disease; ARWR Stock Jumps

Arrowhead Pharma posted positive clinical trials data on a promising drug to treat a rare genetic liver disease, and ARWR stock soared near a nine-moth high; shares of rival Dicerna also jumped.

Yahoo | September 16, 2020

Why Arrowhead Pharmaceuticals Stock Is Soaring Today

Shares of Arrowhead Pharmaceuticals (NASDAQ: ARWR) are up by 49.9% as of 11:35 a.m. EDT on Wednesday, after rising by as much as 51.1% earlier today. Investors are bidding up shares of the biopharmaceutical company today following the release of interim data from a phase 2 clinical trial for one of its pipeline candidates, ARO-AAT. Arrowhead Pharma is developing ARO-AAT as a treatment for liver disease associated with alpha-1 antitrypsin deficiency (AATD).

Yahoo | September 16, 2020

Why Arrowhead Pharma's Stock Is Trading Higher Today

Arrowhead Pharmaceuticals (NASDAQ: ARWR) shares are trading higher on Wednesday after the company announced positive interim 24-week liver biopsy results in four subjects from AROAAT2002, an open-label Phase 2 clinical study of ARO-AAT, the company's second-generation investigational RNA interference therapeutic.Arrowhead Pharmaceuticals is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases.> $ARWR Over 40% Move On The Day | Benzinga Pro Market Alert> > -- Benzinga (@Benzinga) September 16, 2020Click here to start a free tr...

Yahoo | September 16, 2020

Read More 'ARWR' Stories Here

ARWR Price Returns

1-mo 1.73%
3-mo 24.56%
6-mo 64.63%
1-year 57.27%
3-year 1,320.81%
5-year 523.30%
YTD -27.87%
2019 410.71%
2018 237.50%
2017 137.42%
2016 -74.80%
2015 -16.67%

Continue Researching ARWR

Here are a few links from around the web to help you further your research on Arrowhead Pharmaceuticals Inc's stock as an investment opportunity:

Arrowhead Pharmaceuticals Inc (ARWR) Stock Price | Nasdaq
Arrowhead Pharmaceuticals Inc (ARWR) Stock Quote, History and News - Yahoo Finance
Arrowhead Pharmaceuticals Inc (ARWR) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6998 seconds.